Study on efficacy of tocilizumab in moderate to severe covid 19 infection
Background: Cytokine Storm Release (CRS) is considered as major culprit for high mortality in Covid 19. Tocilizumab has shown promising results in initial trials by controlling CRS. We present our observations on Tocilizumab use.